CL2021000300A1 - Combinación de inmunoterapias con inhibidores de mdm2 - Google Patents

Combinación de inmunoterapias con inhibidores de mdm2

Info

Publication number
CL2021000300A1
CL2021000300A1 CL2021000300A CL2021000300A CL2021000300A1 CL 2021000300 A1 CL2021000300 A1 CL 2021000300A1 CL 2021000300 A CL2021000300 A CL 2021000300A CL 2021000300 A CL2021000300 A CL 2021000300A CL 2021000300 A1 CL2021000300 A1 CL 2021000300A1
Authority
CL
Chile
Prior art keywords
combination
immunotherapies
mdm2 inhibitors
effective amount
mdm2
Prior art date
Application number
CL2021000300A
Other languages
English (en)
Inventor
Dajun Yang
Yifan Zhai
Douglas Dong Fang
Qiuqiong Tang
Original Assignee
Ascentage Pharma Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascentage Pharma Suzhou Co Ltd filed Critical Ascentage Pharma Suzhou Co Ltd
Publication of CL2021000300A1 publication Critical patent/CL2021000300A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se dan a conocer en el presente documento terapias de combinación que comprenden una cantidad eficaz de un modulador de la molécula de punto de control inmunitario; y una cantidad eficaz de un inhibidor de MDM2.
CL2021000300A 2018-08-08 2021-02-04 Combinación de inmunoterapias con inhibidores de mdm2 CL2021000300A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2018099280 2018-08-08
CN2018124866 2018-12-28
CN2019073720 2019-01-29
US201962853069P 2019-05-27 2019-05-27

Publications (1)

Publication Number Publication Date
CL2021000300A1 true CL2021000300A1 (es) 2021-10-29

Family

ID=69414548

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000300A CL2021000300A1 (es) 2018-08-08 2021-02-04 Combinación de inmunoterapias con inhibidores de mdm2

Country Status (11)

Country Link
US (1) US20220175725A1 (es)
EP (1) EP3833445A4 (es)
JP (1) JP2021534088A (es)
KR (1) KR20210073490A (es)
CN (1) CN110812478B (es)
AU (1) AU2019316865A1 (es)
BR (1) BR112021002303A2 (es)
CL (1) CL2021000300A1 (es)
MX (1) MX2020013728A (es)
TW (1) TWI786322B (es)
WO (1) WO2020030016A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020169073A1 (en) * 2019-02-24 2020-08-27 Ascentage Pharma (Suzhou) Co., Ltd. Treatment methods and biomarkers for mdm2 inhibitors
EP4003332A4 (en) * 2019-07-26 2023-05-10 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND ITS USE FOR PREVENTING AND/OR TREATING A DISEASE
CN113337602A (zh) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
WO2021207598A1 (en) * 2020-04-10 2021-10-14 Aprea Therapeutics, Inc. Combination treatment with an agonist of p53 and a second therapeutic agent
CN113521064A (zh) * 2020-04-14 2021-10-22 苏州亚盛药业有限公司 Mdm2抑制剂的新用途
CN113801120B (zh) * 2020-06-15 2024-03-22 苏州亚盛药业有限公司 Mdm2抑制剂的微悬浮液以及治疗应用
CN116261455A (zh) * 2020-09-25 2023-06-13 苏州亚盛药业有限公司 一种药物组合物及其在治疗癌症中的用途
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022177995A1 (en) * 2021-02-17 2022-08-25 University Of Florida Research Foundation, Incorporated Anti-lair1 antibodies for the treatment of cancer
AU2022338459A1 (en) 2021-09-01 2024-03-14 Cross Technology Labo Co.,Ltd. Battery having electronic conduction function via electric double layer capacitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608667SA (en) * 2014-04-17 2016-11-29 Univ Michigan Mdm2 inhibitors and therapeutic methods using the same
CA2960824A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
CN109415336B (zh) * 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
AU2018248586A1 (en) * 2017-04-05 2019-09-05 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Also Published As

Publication number Publication date
WO2020030016A1 (en) 2020-02-13
TW202021582A (zh) 2020-06-16
JP2021534088A (ja) 2021-12-09
MX2020013728A (es) 2021-05-27
KR20210073490A (ko) 2021-06-18
BR112021002303A2 (pt) 2021-05-04
EP3833445A4 (en) 2022-04-27
US20220175725A1 (en) 2022-06-09
EP3833445A1 (en) 2021-06-16
CN110812478B (zh) 2021-05-25
CN110812478A (zh) 2020-02-21
AU2019316865A1 (en) 2020-12-17
TWI786322B (zh) 2022-12-11

Similar Documents

Publication Publication Date Title
CL2021000300A1 (es) Combinación de inmunoterapias con inhibidores de mdm2
MX2024005976A (es) Un anticuerpo anti-tigit, un anticuerpo anti-pvrig y un anticuerpo anti-pd-1 para usarse en el tratamiento de cancer.
CL2021001433A1 (es) Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control
BR112018006811A2 (pt) compostos terapêuticos e métodos
CL2018002467A1 (es) El uso de moduladores de receptores de glucocorticoides para potenciar los inhibidores de checkpoint
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
BR112018013995A2 (pt) terapia de combinação de vírus oncolítico e inibidor de ponto de verificação
PE20151897A1 (es) Interfaz de sellado para un cierre de telecomunicaciones
CO2018013104A2 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso
BR112017017457A2 (pt) composição hemostática e dispositivo hemostático (variantes)
CL2018000748A1 (es) Elemento corredizo con dispositivo de obturacion y elemento de obturacion
BR112018074718A2 (pt) composição líquida não oleosa, não aquosa, e, método de controle de nematódeos.
BR112018069927A2 (pt) terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação
MX2021010119A (es) Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
CL2022001540A1 (es) Uso de inhibidores de atr en combinación con inhibidores de parp.
BR112017027266A2 (pt) conduto valvulado e método para fabricação do mesmo
BR112019017714A2 (pt) Dispositivo e método para reforçar integridade de fluxo de controle de aplicação de software
CL2021001363A1 (es) Métodos de tratamiento de enfermedades con inhibidores de magl.
CO2021000087A2 (es) Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x
PE20220129A1 (es) Tratamiento de combinacion para tumores solidos usando docetaxel y un inhibidor de cyp3a
CL2018001129A1 (es) Parche adhesivo con huecos
EA201891643A3 (ru) Магнитное уплотнение для узла лент конвейера
CL2021001691A1 (es) Película de envasado con elastómero de poliuretano termoplástico
BR112018001613A2 (pt) riser dinâmico flexível para intervenção de poço submarino
EP3886836A4 (en) METHODS FOR MODULATION OF WBC ACTIVATION AND PLATE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES